Cyllene Therapeutics
PrivateLast Round
Series C
Jul 7, 2026
Total Funding Raised
$93.95M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Cyllene Therapeutics operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Series C round in July 2026.
Cyllene Therapeutics is a biotechnology company that develops non-replicating HSV-1 vector technology for neurological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cyllene Therapeutics Comparables
Compare Cyllene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LEO Pharma | 76% | |
| Sumitomo Pharma Co., Ltd. | 74% | |
| Guangzhou Yinming Biomedical Technology | 64% |
For institutional investors. Book with your work email.
Cyllene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 7, 2026 | ||||
| Series B | Feb 20, 2025 | ||||
| Series A Extension | Jul 13, 2023 | ||||
| Series A | Mar 1, 2021 | ||||
| Seed | May 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cyllene Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SCI Ventures | Series B |
| GordonMD Global Investments | Series C |
| Andera Partners | Series C, Series B |
| M Ventures | Series C |
| Bpifrance | Series B, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 20% QoQ, from 25 to 30 employees.
- Jul 7, 2026
$38M round led by GordonMD Global Investments and M Ventures.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 7, 2026
Cyllene Tx presents interim data showing EG110A reduces urinary incontinence episodes in people with spinal cord injury at the International Continence Society conference in the Netherlands on Oct 7th '26.
For institutional investors. Book with your work email.
Cyllene Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cyllene Therapeutics's valuation, stock price, and market status.
Is Cyllene Therapeutics a public or private company?
Cyllene Therapeutics is a private company.
What is the current stock price of Cyllene Therapeutics?
Cyllene Therapeutics is a private company, so its shares have no public market price. Caplight tracks Cyllene Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cyllene Therapeutics worth (valuation)?
Valuation information for Cyllene Therapeutics is not publicly available.
Can I buy Cyllene Therapeutics stock?
Cyllene Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cyllene Therapeutics's last funding round?
Cyllene Therapeutics's most recent funding round was Series C on July 7, 2026.
Who are the main investors in Cyllene Therapeutics?
Key investors in Cyllene Therapeutics include GordonMD Global Investments, Andera Partners, M Ventures, Bpifrance.
Will Cyllene Therapeutics IPO soon?
No public IPO plans have been announced for Cyllene Therapeutics.
How can I track Cyllene Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Cyllene Therapeutics's shares on secondary markets.